Your Trusted Brand for Over 35 Years

Age-Related Macular Degeneration References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Macular Degeneration Partnership. Accessed April 10, 2012.
  2. Klein R, Klein BE, et al. Prevalence of age-related macular degeneration in the U.S. population. Arch Ophthalmol. 2011;129(1):75-80.
  3. Haddad S, Chen CA, Santangelo S, Seddon JM. The genetics of age-related macular degeneration: A review of progress to date. Survey of Ophthalmology. 2006 Jul;51(4):316-363.
  4. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355(14):1474–1485.
  5. Kaufman PL, Alm A. Adler’s physiology of the eye-clinical application. Mosby: New York; 2003. 319-47.
  6. Curcio CA, Johnson M, Huang JD, Rudolf, M. Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration. J Lipid Res. 2010 Mar;51(3):451-67.
  7. Seddon JM, Gensler G, Klein ML, Milton RC. C-reactive protein and homocysteine are associated with dietary and behavioral risk factors for age-related macular degeneration. Nutrition. 2006;22(4):441-3.
  8. Klein R, Klein BE, et al. The Beaver Dam Eye Study. Ophthalmology. 2007 Feb;114(2):253-262.
  9. Friedman E. Update of the vascular model of AMD. Br J Ophthalmology. 2004 Feb;88(2):161-163.
  10. Bird AC. Therapeutic targets in age-related macular disease. J Clin Invest. 2010 Sep;120(9):3033-41.
  11. Patel N, Adewoyin T, Chong NV. Age-related macular degeneration: a perspective on genetic studies. Eye (Lond). 2008 Jun;22(6):768-76.
  12. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye (Lond). 2005 Sep;19(9):935-44.
  13. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010 Dec 13;10:31.
  14. Hammond BR Jr, Wooten BR, Snodderly DM. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision Res. 1996 Sep;36(18):3003-9.
  15. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006 Jan;90(1):75-80.
  16. Drobek-Słowik M, Karczewicz D, Safranow K. [The potential role of oxidative stress in the pathogenesis of the age-related macular degeneration (AMD)]. Postepy Hig Med Dosw (Online). 2007;61:28-37.
  17. Babizhayev MA. New concept in nutrition for the maintenance of the aging eye redox regulation and therapeutic treatment of cataract disease; synergism of natural antioxidant imidazole-containing amino acid-based compounds, chaperone, and glutathione boosting agents: a systemic perspective on aging and longevity emerged from studies in humans. Am J Ther. 2010 Jul-Aug;17(4):373-89.
  18. Brubaker RF, Bourne WM, et al. Ascorbic acid content of human corneal epithelium. Invest Ophthalmol Vis Sci 2000 Jun;41(7):1681-3.
  19. Zarbin M. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122(4):598-614.
  20. Hollyfield JG, Bonilha VL, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nature Medicine. 2008;14:194-198.
  21. Augustin AJ, Kirchholf J. Inflammation and the pathogenesis of age-related macular degeneration. Expert Opinion on Therapeutic Targets. 2009 Jun;13(6):641-651.
  22. Seddon JM, Gensler, G, Rosner B. C-reactive protein and CHF, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology. 2010 Aug;117(8):1560-1566.
  23. Boekhoorn SS, Vingerling JR, Witteman JC, Hofman A, de Jong PT. C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol. 2007 Oct;125(10):1396-401.
  24. Krohne TU, Hunt S, Holz FG. Effect of 308 nm excimer laser irradiation on retinal pigment epithelium cell viability in vitro. Br J Ophthalmol. 2009 Jan;93(1):91-5. Epub 2008 Oct 24.
  25. Fletcher AE, Bentham GC, Agnew M, et al. Sunlight exposure, antioxidants, and age-related macular degeneration. Arch Ophthalmol. 2008 Oct;126(10):1396-403.
  26. Fraser-Bell S, Wu J, et al. Cardiovascular risk factors and age-related macular degeneration: The Los Angeles Latino Eye Study. Am J Ophthalmol. 2008 Feb;145(2):308.316.
  27. De la Marnierre E, Guigon B, et al. Phototoxic drugs and age-related maculopathy. J Fr Ophthalmol. 2003;26(6):596-601.
  28. Ahmed SS, Lott MN, Marcus DM. The macular xanthophylls. Surv Ophthalmol. 2005 Mar-Apr;50(2):183-93.
  29. Stahl W. Macular carotenoids: lutein and zeaxanthin. Dev Ophthalmol. 2005;38:70-88.
  30. Richer S, Stiles W, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004 Apr;75(4):216-30.
  31. Christen WG, Glynn RJ, et al. Folic acid, vitamin B6 and vitamin B12 in combination with age-related macular degeneration in a randomized trial of women. Arch Intern Med. 2009 Feb 23;169(4):335-41.
  32. Tan JS, Wang JJ, Flood V, Mitchell P. Dietary fatty acids and the 10-year incidence of age-related macular degeneration: The Blue Mountains Eye study. Arch Ophthalmol. 2009 May;127(5):656-665.
  33. Delcourt C, Carriere I, et al. Dietary fat and the risk of age-related maculopathy: the POLANUT Study. European Journal of Clinical Nutrition. 2007 Nov;61(11):1341-1344.
  34. Chong ET, Simpson JA, et al. Red meat and chicken consumption and its association with age-related macular degeneration. Amer J of Epidemiology. 2009 Feb;169(7):867-876.
  35. Chong EW, Robman LD, et al. Fat consumption and its association with age-related macular degeneration. Arch Ophthalmol. 2009 May;127(5):674-680.
  36. Tan AG, Mitchell P, Flood VM, Bulutsky G, Rochtchine E, Cumming RG, Wang JJ. Antioxidant nutrient intake and the long-term incidence of age-related cataract: the Blue Mountains Eye Study. Am J of Clin Nutr. 2008 Jun;87(6):1899-1905.
  37. Chakravarthy U, Adamis AP, et al. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006 Sep;113(9):1508.e1-25.
  38. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.
  39. Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol. 2006 Jul;142(1):141-3.
  40. Foundation of the American Academy of Ophthalomology. Accessed 1/20/11.
  41. Wormald R, Evans JR, Smeeth LL, Henshaw KS. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. 2007;3.
  42. Food and Drug Administration. Avastin (bevacizumab) Information. Update 11/18/2011. Available at: Accessed 4/20/2012
  43. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30;351(27):2805-16.
  44. Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmol. 2006 Oct;124(10):1478-9.
  45. Regeneron Pharmaceuticals and Bayer HealthCare. Abstract Feb. 2011 at Angiogenesis Conference. Accessed 1/20/11.
  46. Miller JW. Treatment of age-related macular degeneration: beyond VEGF. Jpn J Ophthalmol. 2010 Nov;54(6):523-8.
  47. Yanoff M, Duker JS. Ophthalmology 2nd ed. St. Louis: Mosby; 2004: 925-33.
  48. Bressler NM, Bressler SB, Childs AL, et al. Surgery for subfoveal choroidal neovascularization lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology. 2004 Nov;111(11):1993-2006.
  49. Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization lesions of age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology. 2004 Nov;111(11):1967-80.
  50. Hudson HL, Stulting RD, et al. IMT002 Study Group. Implantable telescope for end-stage age-related macular degeneration: Long-term visual acuity and safety outcomes. Am J Ophthalmol. 2008;146:664-673.
  51. Implantable Miniature Telescope. FDA labeling documentation for approval and use. Available at: Accessed 1/20/11.
  52. Bucolo C, Drago F, Lin LR, Reddy VN. Neuroactive steroids protect retinal pigment epithelium against oxidative stress. Neuroreport. 2005 Aug 1;16(11):1203-07.
  53. Tamer C, Oksuz H, Sogut S. Serum dehydroepiandrosterone sulphate level in age-related macular degeneration. Am J Ophthalmol. 2007 Feb;143(2):212-6.
  54. Dzugan SA, Arnold Smith R. Hypercholesterolemia treatment: a new hypothesis or just an accident? Med Hypotheses. 2002 Dec;59(6):751-6.
  55. Edwards DR, Gallins P, Polk M, et al. Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms. Invest Ophthalmol Vis Sci. 2010 Apr;51(4):1873-9.
  56. Rastmanesh R. Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity. Med Hypotheses. 2011 Jan;76(1):79-85. Epub 2010 Sep 29.
  57. Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP. Role of melatonin in the eye and ocular dysfunctions. Vis Neurosci. 2006 Nov;23(6):853-62.
  58. Yi C, Pan X, Yan H, Guo M, Pierpaoli W. Effects of melatonin in age-related macular degeneration. Ann NY Acad Sci. 2005 Dec;1057:384-92.
  59. Yu X, Zhu J, Mi M, Chen W, Pan Q, Wei M. Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Med Oncol. 2010 Dec.
  60. Wang B, Zou Y, Li H, Pan JS, Yuan ZL. Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1alpha in a mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther. 2005 Apr;21(2):107-113.
  61. Landrum JT, Bone RA. Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 2001 Jan 1;385(1):28-40.
  62. Chong ET, Kreis AJ, Wong TY, et al. Dietary Omega-3 Fatty Acid and Fish Intake in the Primary Prevention of Age-Related Macular Degeneration: A Systematic Review and Meta-analysis. Arch Ophthalmol. 2008;126(6):826-833.
  63. Rapp LM, Maple SS, et al. Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1200-9.
  64. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34.
  65. Kaya S, Weigert G, et al. Effect of lutein supplementation on macular pigment optical density in patients with AMD. Acta Ophthalmologica. 2010 Sep;88(s246).
  66. Johnson EJ, Maras JE, Rasmussen HM, et al. Intake of lutein and zeaxanthin differ with age, sex, and ethnicity. J Am Diet Assoc. 2010 Sep;110(9):1357-62.
  67. Bone RA, Landrum JT, et al. Lutein and zeaxanthin in the eyes, serum and diet of human subjects. Exp Eye Res. 2000 Sep;71(3):239-45.
  68. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr. 2003;23:171-201.
  69. Bone RA, Landrum JT, Cao Y, Howard AN, Alvarez-Calderon F. Macular pigment response to a supplement containing meso-zeaxanthin, lutein and zeaxanthin. Nutr Metab (Lond). 2007 May 11;4:12.
  70. Quantum Nutritionals, data on file
  71. Amorini AM, Fazzina G, Lazzarino G, et al. Activity and mechanism of the antioxidant properties of cyanidin-3-O-beta-glucopyranoside. Free Radic Res. 2001 Dec;35(6):953-66.
  72. Zafra-Stone S, Yasmin T, et al. Berry anthocyanins as novel antioxidants in human health and disease prevention. Molecular Nutrition & Food Research. 2007 Jun;51(6):675-683.
  73. Fursova AZ, Gesarevich OG, et al. Dietary supplementation with bilberry extract prevent macular degeneration and cataracts in senesce-accelerated OXYS rats. Adv Gerontology. 2005;16:76-79.
  74. Milbury PE, Graf B, et al. Bilberry (Vaccinium myrtillus) Anthocyanins modulate heme oxygenase-1 and glutathione S-transferase-pi expression in ARPE-19 cells. Invest. Ophthalmol. Vis. Sci. 2007 May;48(5):2343-2349.
  75. Nakaishi H, Matsumoto H, Tominaga S, Hirayama M. Effects of black currant anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans. Alt Med Rev. 2000 Dec;5(6):553-62.
  76. Roberts LJ, Oates JA, et al. The relationship between dose of Vitamin E and suppression of oxidative stress in humans. Free Radical Biology and Medicine. 2007 Nov;43(10):1388-1393.
  77. Miyazawa T, Nakagawa K, Kudo M, Muraishi K, Someya K. Direct intestinal absorption of red fruit anthocyanins, cyanidin-3-glucoside and cyanidin-3,5-diglucoside, into rats and humans. J Agric Food Chem. 1999 Mar;47(3):1083-91.
  78. Tsuda T, Horio F, Osawa T. Absorption and metabolism of cyanidin 3-O-beta-D-glucoside in rats. FEBS Lett. 1999 Apr 23;449(2-3):179-82.
  79. Matsumoto H, Inaba H, Kishi M, Tominaga S, Hirayama M, Tsuda T. Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms. J Agric Food Chem. 2001 Mar;49(3):1546-51.
  80. Acquaviva R, Russo A, Galvano F, et al. Cyanidin and cyanidin 3-O-beta-D -glucoside as DNA cleavage protectors and antioxidants. Cell Biol Toxicol. 2003 Aug;19(4):243-52.
  81. Riso P, Visioli F, Gardana C, et al. Effects of blood orange juice intake on antioxidant bioavailability and on different markers related to oxidative stress. J Agric Food Chem. 2005 Feb 23;53(4):941-7.
  82. Serraino I, Dugo L, Dugo P, et al. Protective effects of cyanidin-3-O-glucoside from blackberry extract against peroxynitrite-induced endothelial dysfunction and vascular failure. Life Sci. 2003 Jul 18;73(9):1097-114.
  83. Pergola C, Rossi A, Dugo P, Cuzzocrea S, Sautebin L. Inhibition of nitric oxide biosynthesis by anthocyanin fraction of blackberry extract. Nitric Oxide. 2006 Aug;15(1):30-9.
  84. Xu JW, Ikeda K, Yamori Y. Cyanidin-3-glucoside regulates phosphorylation of endothelial nitric oxide synthase. FEBS Lett. 2004 Sep 10;574(1-3):176-80.
  85. Tsuda T, Horio F, Uchida K, Aoki H, Osawa T. Dietary cyanidin 3-O-beta-D-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice. J Nutr. 2003 Jul;133(7):2125-30.
  86. Tsuda T, Ueno Y, Aoki H, et al. Anthocyanin enhances adipocytokine secretion and adipocyte-specific gene expression in isolated rat adipocytes. Biochem Biophys Res Commun. 2004 Mar 26;316(1):149-57.
  87. Fimognari C, Berti F, Nusse M, Cantelli-Forti G, Hrelia P. Induction of apoptosis in two human leukemia cell lines as well as differentiation in human promyelocytic cells by cyanidin-3-O-beta-glucopyranoside. Biochem Pharmacol. 2004 Jun 1;67(11):2047-56.
  88. Chen PN, Chu SC, Chiou HL, Chiang CL, Yang SF, Hsieh YS. Cyanidin 3-glucoside and peonidin 3-glucoside inhibit tumor cell growth and induce apoptosis in vitro and suppress tumor growth in vivo. Nutr Cancer. 2005;53(2):232-43.
  89. Serafino A, Sinibaldi-Vallebona P, Lazzarino G, et al. Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside. FASEB J. 2004 Dec;18(15):1940-2.
  90. Tarozzi A, Morroni F, Merlicco A, et al. Neuro-protective effects of cyanidin 3-O-glucopyranoside on amyloid beta (25-35) oligomer-induced toxicity. Neurosci Lett. 2010 Apr 5;473(2):72-6.
  91. Majumdar S, Srirangam R. Potential of the bioflavonoids in the prevention/treatment of ocular disorders. Journal of Pharmacy and Pharmacology. 2010 Aug;62(8):951-965.
  92. Pfleger CM, et al. Grape-seed polyphenolic extract improves the eye phenotype in a Drosophila model of tauopathy. Int J Alzheimers Dis. 2010 Aug 24;2010. pii: 576357.
  93. Li M, Ma YB, Gao HQ, Li BY, Cheng M, Xu L, Li XL, Li XH. A novel approach of proteomics to study the mechanism of action of grape seed proanthocyanidin extracts on diabetic retinopathy in rats. Chin Med J (Engl). 2008 Dec 20;121(24):2544-52.
  94. Liu M, Liu RH, Song BB, Li CF, Lin LQ, Zhang CP, Zhao JL, Liu JR. Antiangiogenetic effects of 4 varieties of grapes in vitro. J Food Sci. 2010 Aug 1;75(6):T99-104.
  95. Rakici O, Kiziltepe U, Coskun B, et al. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol. 2005 Nov 2;105(2):209-15.
  96. Kim YH, Kim YS, Roh GS, et al. Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol. 2012 Feb;90(1):e31-7.
  97. Hua J Guerin KI, Chen J, et al. Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice. Invest Ophthalmol Vis Sci. 2011 Apr 25;52(5):2809-16. Print 2011 Apr.
  98. Kubota S, Kurihara T, Ebinuma M, et al. veratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am J Pathol. 2010 Oct;177(4):1725-31.
  99. Pintea A, Rugina D, Pop R, et al. Antioxidant effect of trans-resveratrol in cultured human retinal pigment epithelial cells. J Ocul Pharmacol Ther. 2011 Aug;27(4):315-21.
  100. Thiagarajan G, Chandani S, et al. Molecular and cellular assessment of Ginkgo biloba extract as a possible ophthalmic drug. Experimental Eye Research. 2002 Oct;75(4):4231-430.
  101. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety and uses. Journal of Food Science. 2008 Jan/Feb;73(1):R14-R19.
  102. Peyman GA, Kivilcim M, Morales AM, DellaCroce JT, Conway MD. Inhibition of corneal angiogenesis by ascorbic acid in the rat model. Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1461-7.
  103. Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosine-related antioxidants: a review. Curr Med Chem. 2005;12(20):2293-315.
  104. Specht S, Organisciak DT, et al. Continuing damage to rat retinal DNA during darkness following light exposure. Photochem Photobiol. 2000 May;71(5):559-66.
  105. Williams DL, Munday P. The effect of topical antioxidant formulation including N-actetyl carnosine on canine cataract: a preliminary study. Vet Ophthalmol. 2006 Sep-Oct;9(5):311-6.
  106. Babizhayez MA, Burke L, Micans P, Richer SP. N-acteylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: Glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000 patient population. Clin Interv Aging. 2009 May;4:31-50.
  107. Head KA. Natural therapies for ocular disorders, part 2: cataracts and glaucoma. Altern Med Rev. 2001 Apr;6(2):141-66.
  108. King AJ. Should we be considering selenium in glaucoma? Br J Ophthalmol. 2009;93(9):1132-1doi:10.1136/bjo.2008.141218.
  109. Lu L, Oveson BC, et al. Increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage. Antioxidants & Redox Signaling. 2009 Apr;11(4): 715-724. doi:10.1089/ars.2008.2171.
  110. Blasi MA, Bovina C, et al. Does coenzyme Q10 play a role in opposing oxidative stress in patients with age-related macular degeneration? Ophthalmologica. 2001 Jan-Feb;215(1):51-4.
  111. Jarrett SG, Lewin AS, Boulton ME. The importance of mitochondria in age-related and inherited eye disorders. Ophthalmic Res. 2010;44(3):179-90.
  112. Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica. 2005 May-Jun;219(3):154-66.
  113. Lopez B, Ubels JL. Artificial tear composition and promotion of recovery of the damaged corneal epithelium. Cornea. 1993 Mar;12(2):115-20.
  114. Hussain AA, Marshall J. Taurine transport pathways in the outer retina in relation to aging and disease. Ocular Transporters in Ophthalmic Diseases and Drug Delivery. Ophthalmology Research 2008(V):217-233.
  115. Dong A, Bing X, et al. Oxidative stress promotes ocular neovascularization. Jour of Cellular Physiol. 2009 Jun;219(3):544-552.
  116. Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmol. Dec 2005;112(12):2076-80.
  117. Rochtchina E, Wang JJ, Flood VM, Mitchell P. Elevated serum homocysteine, low serum vitamin B12, folate, and age-related macular degeneration: The Blue Mountains Eye Study. Am J Ophthalmol. 2007 Feb;143(2):344-6.
  118. Fahed DC, Ghazi NG, Jabbour NM, Fahed CD, Fahed JC, Salti HI. Impact of AREDS in a developing country 5 years after publication of the study. Eur J Ophthalmol. 2010 Jun 30. pii: F1AEDD77-F8C5-4A89-B58F-DD17A6B251AD.
  119. Chiu CJ, Klein R, Milton RC, Gensler G, Taylor A. Does eating particular diets alter risk of age-related macular degeneration in users of the age-related eye disease study supplements? Br J Ophthalmology. June 2doi:10.1136/bjo.2008.143412.
  120. Newsome DA. A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. Curr. Eye Res. 2008;33(7):591-598.